Cargando…

The GDAP1 p.Glu222Lys Variant-Weak Pathogenic Effect, Cumulative Effect of Weak Sequence Variants, or Synergy of Both Factors?

Charcot–Marie–Tooth disorders (CMT) represent a highly heterogeneous group of diseases of the peripheral nervous system in which more than 100 genes are involved. In some CMT patients, a few weak sequence variants toward other CMT genes are detected instead of one leading CMT mutation. Thus, the pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Kabzińska, Dagmara, Chabros, Katarzyna, Kamińska, Joanna, Kochański, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498914/
https://www.ncbi.nlm.nih.gov/pubmed/36140714
http://dx.doi.org/10.3390/genes13091546
_version_ 1784794878727684096
author Kabzińska, Dagmara
Chabros, Katarzyna
Kamińska, Joanna
Kochański, Andrzej
author_facet Kabzińska, Dagmara
Chabros, Katarzyna
Kamińska, Joanna
Kochański, Andrzej
author_sort Kabzińska, Dagmara
collection PubMed
description Charcot–Marie–Tooth disorders (CMT) represent a highly heterogeneous group of diseases of the peripheral nervous system in which more than 100 genes are involved. In some CMT patients, a few weak sequence variants toward other CMT genes are detected instead of one leading CMT mutation. Thus, the presence of a few variants in different CMT-associated genes raises the question concerning the pathogenic status of one of them. In this study, we aimed to analyze the pathogenic effect of c.664G>A, p.Glu222Lys variant in the GDAP1 gene, whose mutations are known to be causative for CMT type 4A (CMT4A). Due to low penetrance and a rare occurrence limited to five patients from two Polish families affected by the CMT phenotype, there is doubt as to whether we are dealing with real pathogenic mutation. Thus, we aimed to study the pathogenic effect of the c.664G>A, p.Glu222Lys variant in its natural environment, i.e., the neuronal SH-SY5Y cell line. Additionally, we have checked the pathogenic status of p.Glu222Lys in the broader context of the whole exome. We also have analyzed the impact of GDAP1 gene mutations on the morphology of the transfected cells. Despite the use of several tests to determine the pathogenicity of the p.Glu222Lys variant, we cannot point to one that would definitively solve the problem of pathogenicity.
format Online
Article
Text
id pubmed-9498914
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94989142022-09-23 The GDAP1 p.Glu222Lys Variant-Weak Pathogenic Effect, Cumulative Effect of Weak Sequence Variants, or Synergy of Both Factors? Kabzińska, Dagmara Chabros, Katarzyna Kamińska, Joanna Kochański, Andrzej Genes (Basel) Article Charcot–Marie–Tooth disorders (CMT) represent a highly heterogeneous group of diseases of the peripheral nervous system in which more than 100 genes are involved. In some CMT patients, a few weak sequence variants toward other CMT genes are detected instead of one leading CMT mutation. Thus, the presence of a few variants in different CMT-associated genes raises the question concerning the pathogenic status of one of them. In this study, we aimed to analyze the pathogenic effect of c.664G>A, p.Glu222Lys variant in the GDAP1 gene, whose mutations are known to be causative for CMT type 4A (CMT4A). Due to low penetrance and a rare occurrence limited to five patients from two Polish families affected by the CMT phenotype, there is doubt as to whether we are dealing with real pathogenic mutation. Thus, we aimed to study the pathogenic effect of the c.664G>A, p.Glu222Lys variant in its natural environment, i.e., the neuronal SH-SY5Y cell line. Additionally, we have checked the pathogenic status of p.Glu222Lys in the broader context of the whole exome. We also have analyzed the impact of GDAP1 gene mutations on the morphology of the transfected cells. Despite the use of several tests to determine the pathogenicity of the p.Glu222Lys variant, we cannot point to one that would definitively solve the problem of pathogenicity. MDPI 2022-08-27 /pmc/articles/PMC9498914/ /pubmed/36140714 http://dx.doi.org/10.3390/genes13091546 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kabzińska, Dagmara
Chabros, Katarzyna
Kamińska, Joanna
Kochański, Andrzej
The GDAP1 p.Glu222Lys Variant-Weak Pathogenic Effect, Cumulative Effect of Weak Sequence Variants, or Synergy of Both Factors?
title The GDAP1 p.Glu222Lys Variant-Weak Pathogenic Effect, Cumulative Effect of Weak Sequence Variants, or Synergy of Both Factors?
title_full The GDAP1 p.Glu222Lys Variant-Weak Pathogenic Effect, Cumulative Effect of Weak Sequence Variants, or Synergy of Both Factors?
title_fullStr The GDAP1 p.Glu222Lys Variant-Weak Pathogenic Effect, Cumulative Effect of Weak Sequence Variants, or Synergy of Both Factors?
title_full_unstemmed The GDAP1 p.Glu222Lys Variant-Weak Pathogenic Effect, Cumulative Effect of Weak Sequence Variants, or Synergy of Both Factors?
title_short The GDAP1 p.Glu222Lys Variant-Weak Pathogenic Effect, Cumulative Effect of Weak Sequence Variants, or Synergy of Both Factors?
title_sort gdap1 p.glu222lys variant-weak pathogenic effect, cumulative effect of weak sequence variants, or synergy of both factors?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498914/
https://www.ncbi.nlm.nih.gov/pubmed/36140714
http://dx.doi.org/10.3390/genes13091546
work_keys_str_mv AT kabzinskadagmara thegdap1pglu222lysvariantweakpathogeniceffectcumulativeeffectofweaksequencevariantsorsynergyofbothfactors
AT chabroskatarzyna thegdap1pglu222lysvariantweakpathogeniceffectcumulativeeffectofweaksequencevariantsorsynergyofbothfactors
AT kaminskajoanna thegdap1pglu222lysvariantweakpathogeniceffectcumulativeeffectofweaksequencevariantsorsynergyofbothfactors
AT kochanskiandrzej thegdap1pglu222lysvariantweakpathogeniceffectcumulativeeffectofweaksequencevariantsorsynergyofbothfactors
AT kabzinskadagmara gdap1pglu222lysvariantweakpathogeniceffectcumulativeeffectofweaksequencevariantsorsynergyofbothfactors
AT chabroskatarzyna gdap1pglu222lysvariantweakpathogeniceffectcumulativeeffectofweaksequencevariantsorsynergyofbothfactors
AT kaminskajoanna gdap1pglu222lysvariantweakpathogeniceffectcumulativeeffectofweaksequencevariantsorsynergyofbothfactors
AT kochanskiandrzej gdap1pglu222lysvariantweakpathogeniceffectcumulativeeffectofweaksequencevariantsorsynergyofbothfactors